GLP-1 Medicines and Gallstones: Risk, Warning Signs and When to Seek Help
By Dr. Moxit Shah, DM Endocrinology
Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Ahmedabad
Medical information reviewed: 17 November 2026. Based on prescribing information and published clinical-trial evidence.
Can Mounjaro, Ozempic or Wegovy cause gallstones? Medicines used for diabetes and medical weight loss—including the GLP-1 receptor agonist semaglutide and the dual GIP/GLP-1 receptor agonist tirzepatide—have important benefits for appropriately selected patients. However, gallstones and gallbladder inflammation are recognized potential adverse events. The risk is not the same for everyone, and most people taking these medicines do not develop a gallbladder complication.
Quick answer: GLP-1 treatment has been associated with a modestly increased risk of gallbladder or biliary disease, particularly at higher doses, over longer periods, and during weight-loss treatment. Sudden or persistent pain in the upper right abdomen, especially with fever, vomiting or jaundice, needs prompt medical assessment—not simply a remedy for medication-related nausea.
What are gallstones and gallbladder disease?
The gallbladder is a small organ beneath the liver that stores bile, a fluid important for digesting fats. Gallstones are solid deposits that can form within it. Some never cause symptoms, while others may temporarily block bile flow or trigger inflammation.
| Term | Meaning | Typical concern |
|---|---|---|
| Cholelithiasis | Gallstones within the gallbladder | May be asymptomatic or cause biliary pain |
| Biliary colic | Pain associated with transient blockage of a bile duct or gallbladder outlet | Steady upper abdominal pain, often after a meal |
| Cholecystitis | Inflammation of the gallbladder | Persistent pain, sometimes with fever; urgent evaluation |
| Cholangitis or bile-duct obstruction | Infection or blockage involving bile drainage | Can present with pain, fever and jaundice; may be an emergency |
The same abdominal symptoms can have other causes, including gastritis, pancreatitis or ulcer disease. A healthcare professional may need to investigate rather than assume gallstones are responsible.
Do GLP-1 medicines actually increase gallstone risk?
Yes, evidence supports an increased risk at the group level. A systematic review and meta-analysis published in JAMA Internal Medicine included 76 randomized clinical trials with 103,371 participants. GLP-1 receptor agonist treatment was associated with an approximately 37% relative increase in gallbladder or biliary disease compared with control treatments (relative risk 1.37). However, relative risk alone can sound larger than the absolute chance of developing the condition.
The researchers estimated approximately 27 additional gallbladder or biliary events per 10,000 treated patients per year across the included trials. This is an average estimate—not a personalized prediction for any particular medicine, dose or person. Higher-dose, longer-duration and weight-loss studies showed stronger associations.
Reference: He and colleagues, JAMA Internal Medicine, 2022.
Gallbladder events in semaglutide and tirzepatide trials
The following examples come from the U.S. prescribing information for the weight-management formulations; their figures reflect different trials and should not be treated as a head-to-head comparison or as India-specific event rates.
| Clinical-trial data | Medicine group | Comparator group |
|---|---|---|
| Semaglutide injection (Wegovy): gallstones | 1.6% | 0.7% with placebo |
| Semaglutide injection (Wegovy): cholecystitis | 0.6% | 0.2% with placebo |
| Tirzepatide (Zepbound): gallstones | 1.1% | 1.0% with placebo |
| Tirzepatide (Zepbound): cholecystitis | 0.7% | 0.2% with placebo |
Semaglutide is available in India under brands including Ozempic and Wegovy; tirzepatide is marketed under brands including Mounjaro and Yurpeak. Zepbound is the U.S. tirzepatide weight-management brand used to identify the trial population above, not an additional Indian generic. Product approval, patient indications and brand presentations must be checked against the applicable Indian product information.
Prescribing references: Wegovy (semaglutide) U.S. label; Zepbound (tirzepatide) U.S. label.
Why might gallstones form during GLP-1 weight-loss treatment?
The relationship is likely multifactorial:
1. Substantial or rapid weight loss
Rapid weight reduction—even without a GLP-1 medicine—can increase the risk of gallstones. Changes in bile composition and gallbladder emptying may contribute. This is one reason an extreme crash diet is not a safe substitute for a sustainable treatment plan.
2. Changes in gallbladder emptying
GLP-1 signaling may affect gastrointestinal motility, including gallbladder emptying. This is one proposed mechanism for the gallbladder association, but the contribution of a direct drug effect versus the effect of weight loss varies and is not completely established.
3. Individual susceptibility
A previous history of gallstones, age, family history, certain metabolic conditions, and other risk factors may affect the baseline likelihood of disease. A person with gallstones may still be eligible for GLP-1 treatment after a careful clinical review, depending on their symptoms and the chosen product.
The goal is not to avoid effective weight loss. It is to use an appropriate medicine with individualized follow-up, nutrition, hydration and prompt attention to warning signs.
Symptoms of gallstones while taking Mounjaro, Ozempic or Wegovy
Possible gallbladder-related warning signs include:
- Upper-right abdominal pain or pain in the upper middle abdomen that may be severe or persistent
- Pain after a meal, sometimes spreading to the back or right shoulder
- Repeated nausea or vomiting accompanying abdominal pain
- Fever or chills, which may signal inflammation or infection
- Yellowing of the eyes or skin, dark urine or pale stools, which may suggest impaired bile drainage
These symptoms deserve medical evaluation, particularly if pain lasts for several hours. Severe persistent abdominal pain, fever, jaundice, repeated vomiting or inability to keep fluids down requires urgent care.
Not every episode of nausea, constipation or bloating is a gallbladder problem. GLP-1 medicines frequently cause digestive symptoms, especially around dose increases, but new focal or persistent pain should not be dismissed as a routine side effect. See our GLP-1 reflux and burping guide for related, less-specific symptoms.
Gallstones versus pancreatitis: What is the difference?
Both may cause upper abdominal pain, nausea and vomiting, and sometimes a gallstone can trigger pancreatitis. Pancreatitis is inflammation of the pancreas; the pain is often severe and persistent and may spread to the back. You cannot reliably distinguish these conditions at home.
Current product information advises discontinuing GLP-1-based therapy when pancreatitis is suspected and obtaining medical evaluation. If you develop severe or persistent abdominal pain, particularly with vomiting or back-radiating pain, seek urgent care and tell the team which medicine you take and when the last dose was given. Do not take the next dose before the treating clinician has assessed the situation.
Do you need an ultrasound before starting GLP-1 medicine?
Not routinely for every symptom-free patient. A blanket ultrasound for all GLP-1 users is not a standard prerequisite solely because they are starting therapy. However, prior gallstones, previous biliary symptoms or new concerning abdominal pain may make targeted assessment appropriate.
When gallbladder disease is suspected, a clinician may recommend:
- Abdominal ultrasonography to assess for gallstones and gallbladder inflammation
- Liver biochemistry, including bilirubin and liver enzymes, when obstruction or inflammation is suspected
- Blood count and inflammatory investigations where clinically indicated
- Lipase testing or additional imaging when pancreatitis or another abdominal emergency is suspected
An ultrasound report that incidentally shows silent gallstones does not automatically mean surgery or immediate permanent discontinuation of GLP-1 treatment. It should be interpreted in the context of symptoms, overall health and treatment goals.
What should you do if gallstones are diagnosed during treatment?
Management is based on symptoms and complications, not simply whether a medicine has been taken:
- Obtain medical evaluation promptly if you have pain, fever, vomiting or jaundice.
- Inform your endocrinologist and treating team about the exact molecule, brand, dose and last administration date.
- Follow the diagnostic and treatment plan. Symptomatic stones or cholecystitis may require a surgical or gastroenterology assessment.
- Review GLP-1 treatment individually. The prescriber may decide to hold, stop or reassess the medicine depending on the suspected condition and clinical severity. Avoid independently restarting after a serious episode.
- Plan safe follow-up for diabetes. If a glucose-lowering medicine is interrupted, the team may need to adjust other treatments to prevent marked hyperglycaemia.
Patients with confirmed acute cholecystitis, pancreatitis or bile-duct infection require care directed at those conditions. Some situations need hospital treatment.
Can you take a GLP-1 medicine after gallbladder removal?
Sometimes, yes. Having had a cholecystectomy does not automatically rule out GLP-1 therapy in every patient, but the reason for surgery, residual bile-duct problems, digestive symptoms and other conditions must be reviewed. A person may still have bile-duct stones or other causes of upper abdominal pain after gallbladder removal.
Whether treatment is appropriate should be decided by the prescribing clinician using the applicable product information and the patient’s individual history.
Seven ways to make GLP-1 weight-loss treatment safer
- Discuss previous gallstones or pancreatitis before treatment begins.
- Avoid extreme fasting or crash diets that produce rapid, poorly supervised weight changes.
- Eat balanced, nutritionally adequate meals rather than trying to lose weight by routinely skipping food.
- Stay adequately hydrated, particularly if nausea or vomiting limits fluid intake; those with heart or kidney conditions may require individualized fluid targets.
- Follow the approved dose-escalation plan and do not accelerate increases independently.
- Report persistent abdominal pain early rather than increasing the dose or ignoring the symptoms.
- Maintain follow-up to review glucose, weight change, food intake, side effects and the continuing benefits of treatment.
For meal-planning support, read What to Eat While Taking GLP-1 Medicines: An Indian Food Guide. For an overview of molecules and brands available in India, see GLP-1 Medicines Available in India in 2026.
Frequently asked questions
Does everyone taking semaglutide develop gallstones?
No. Gallbladder events occur in a minority of patients. Clinical trials and a large meta-analysis suggest an increase compared with control groups, but the overall absolute increase is small.
Is tirzepatide safer for the gallbladder than semaglutide?
The trial percentages cited here come from different studies and do not establish that one medicine is safer than another. Head-to-head safety conclusions require appropriately designed comparative evidence.
Can I keep taking Mounjaro if I already have silent gallstones?
Possibly, after medical review. Silent stones are not automatically an absolute contraindication, but a history of gallbladder disease should be discussed with the prescriber before continuing or changing treatment.
What type of pain suggests gallbladder disease?
Persistent or recurring pain in the upper right or upper middle abdomen, sometimes spreading to the back or right shoulder, is a common presentation. Fever, jaundice or persistent vomiting raises concern for a more serious problem.
Should I stop my medicine if I experience mild nausea?
Mild nausea is relatively common during GLP-1 therapy and does not automatically mean gallbladder disease. If there is severe or persistent pain, repeated vomiting or other alarm symptoms, seek prompt assessment rather than treating it as routine nausea.
Does gallbladder ultrasound need to be repeated every month during GLP-1 treatment?
No. Routine monthly ultrasound screening for every symptom-free patient is not a standard recommendation. Imaging is generally considered when symptoms or clinical history indicate a need.
Can rapid weight loss cause gallstones even without GLP-1 treatment?
Yes. Rapid weight loss itself is a recognized risk factor. This is part of the reason a sustainable medical weight-loss plan is preferable to crash dieting.
Could severe abdominal pain be pancreatitis instead?
Yes. Pancreatitis is another important cause of severe persistent abdominal pain. It may resemble gallbladder disease and needs urgent assessment. Current product safety information advises stopping the medicine when pancreatitis is suspected pending clinical evaluation.
GLP-1 and medical weight-loss care in Ahmedabad
Medical weight-loss therapy requires individualized benefit–risk assessment, appropriate nutrition and monitoring of symptoms. At Vishuddha Diabetes, Thyroid, Weight Loss Clinic, Dr. Moxit Shah, DM Endocrinology, provides assessment and follow-up for diabetes and medical weight-loss treatments, including semaglutide and tirzepatide when appropriate.
Vishuddha Diabetes, Thyroid, Weight Loss Clinic
104–105, Elite Magnum, Bhuyangdev Cross Road, Opp. Utsav Elegance, Vardhmannagar Society, Ghatlodiya, Ahmedabad, Gujarat – 380061, India
Nearby areas: Memnagar and Naranpura
Dr. Moxit Shah, DM Endocrinology
Appointments: +91 99799 92797
Medical references
- He L, et al. GLP-1 Receptor Agonists and Gallbladder/Biliary Disease: Systematic Review and Meta-analysis of 76 Randomized Trials. JAMA Internal Medicine (2022).
- Semaglutide (Wegovy) U.S. Prescribing Information, 2026: Gallbladder Disease and Pancreatitis Precautions.
- Tirzepatide (Zepbound) U.S. Prescribing Information, 2026: Gallbladder Disease and Pancreatitis Precautions.
- NIDDK: Gallstones — Symptoms, Causes, and Warning Signs.
- Indian Council of Medical Research: Standard Treatment Workflow for Gallstone Disease.
Medical disclaimer: This article provides general patient education, not an individual diagnosis or medicine prescription. Report concerning abdominal symptoms promptly, especially severe or persistent pain, fever, jaundice or vomiting. Product indications and prescribing instructions may differ between India and other countries. Never independently increase, restart or substitute GLP-1-based medicines.
